View Filing Data

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2016
Document and Entity Information
Entity Registrant Name	OptimizeRx Corp
Entity Central Index Key	0001448431
Amendment Flag	false
Document Type	S-1
Entity Filer Category	Smaller Reporting Company
Document Period End Date	Mar. 31, 2016

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 7,548,261	$ 8,207,565	$ 3,446,973
Accounts receivable	2,340,765	2,847,450	2,100,381
Prepaid expenses	54,555	70,623	28,093
Total Current Assets	9,943,581	11,125,638	5,575,447
Property and equipment, net	23,076	10,239	12,813
Other Assets
Patent rights, net	817,239	832,884	930,854
Web development costs, net	308,812	340,470	504,643
Security deposit	5,049	5,049	5,049
Total Other Assets	1,131,100	1,178,403	1,440,546
TOTAL ASSETS	11,097,757	12,314,280	7,028,806
Current Liabilities
Accounts payable - trade	195,076	212,191	200,372
Accounts payable - related party		570,000	570,000
Accrued expenses	8,090	6,983	25,459
Revenue share payable	1,502,816	2,355,608	1,502,761
Deferred revenue	845,226	227,002	120,130
Total Liabilities	2,551,208	3,371,784	2,418,722
Stockholders' Equity
Common stock, Value	29,043	29,031	22,867
Preferred stock, Value
Stock warrants	2,294,416	2,329,508	2,153,295
Additional paid-in-capital	32,631,226	32,185,499	27,595,609
Stock payable	663,670	1,132,148	963,063
Deferred stock compensation		(13,800)
Accumulated deficit	(27,071,806)	(26,719,890)	(26,124,750)
Total Stockholders' Equity	8,546,549	8,942,496	4,610,084
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 11,097,757	$ 12,314,280	$ 7,028,806

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Preferred stock, shares issued	0	65
Preferred stock, shares outstanding	0	65
Common stock par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000	500,000,000
Common stock, shares issued	29,043,425	29,030,925	22,867,319
Common stock, shares outstanding	29,043,425	29,030,925	22,867,319

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
NET REVENUE	$ 1,759,528	$ 1,487,553	$ 7,220,678	$ 6,502,962
REVENUE SHARE EXPENSE			3,622,203	3,221,534
COST OF SALES	892,793	756,440
GROSS MARGIN	866,735	731,113	3,598,475	3,281,428
OPERATING EXPENSES
Stock-based compensation			581,106	1,172,242
Depreciation and amortization	50,268	79,668	333,950	264,340
Lawsuit settlement			0	400,000
Other operating expenses			3,280,826	2,471,174
Total Operating expenses	1,228,564	842,610	4,195,882	4,307,756
LOSS FROM OPERATIONS	(361,829)	(111,497)	(597,407)	(1,026,328)
OTHER INCOME (EXPENSE)
Interest income	10,076	296	2,267	935
Interest expense	(163)
TOTAL OTHER INCOME (EXPENSE)	9,913	296	2,267	935
LOSS BEFORE PROVISION FOR INCOME TAXES	(351,916)	(111,201)	(595,140)	(1,025,393)
PROVISION FOR INCOME TAXES			0	0
NET LOSS	$ (351,916)	$ (111,201)	$ (595,140)	$ (1,025,393)
WEIGHTED AVERAGE SHARES OUTSTANDING
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC			24,562,438	22,382,415
BASIC AND DILUTED	29,030,925	22,897,819
NET LOSS PER SHARE
NET LOSS PER SHARE: BASIC (no separate per share amount shown for diluted because loss is antidilutive)			$ (0.02)	$ (0.04)
BASIC AND DILUTED	$ (0.01)	$ 0

Consolidated Statement of Stockholders' Equity - USD ($)	Total	Preferred Stock	Common Stock	Stock Warrants	Additional Paid-in Capital	Stock Payable	Deferred Stock Compensation	Accumulated Deficit
Beginning balance at Dec. 31, 2013	$ 1,668,202	$ 0	$ 14,817	$ 18,148,049	$ 8,875,155	$ 0	$ (270,462)	$ (25,099,357)
Beginning balance, shares at Dec. 31, 2013		65	14,817,496
Issuance of stock options: to employees	272,804				272,804
Issuance of stock options: to consultants	0				16,935		(16,935)
Issuance of common stock: for services	41,667		$ 167		26,812	14,688
Issuance of common stock: for services, shares			167,065
Issuance of common stock: for cash	8,795,032		$ 8,333		8,408,699	378,000
Issuance of common stock: for cash shares			8,333,333
Issuance of common stock: for warrant exercise	$ 0		$ 446	(694,133)	693,687
Issuance of common stock: for warrant exercise, shares	0		445,765
Issue warrants for equity raise	$ 0			1,110,211	(1,110,211)
Issue stock rights to officers	570,375					570,375
Reclassify expired and redeemed warrants	0			(16,410,832)	16,410,832
Expense consulting services	287,397						287,397
Redeem shares for cash	(6,000,000)	$ 0	$ (896)		(5,999,104)
Redeem shares for cash, shares		(65)	(896,340)
Net loss for the year	(1,025,393)							(1,025,393)
Ending balance at Dec. 31, 2014	4,610,084	$ 0	$ 22,867	2,153,295	27,595,609	963,083	0	(26,124,750)
Ending balance, shares at Dec. 31, 2014		0	22,867,319
Issuance of stock options: to employees	253,358				253,358
Issuance of common stock: for services	60,125		$ 153		172,310	(14,688)	(97,650)
Issuance of common stock: for services, shares			152,500
Issuance of common stock: for cash	$ 4,346,446		$ 6,011	176,213	4,164,222
Issuance of common stock: for cash shares			6,011,106
Issuance of common stock: for warrant exercise, shares	0
Issue stock rights to officers	$ 183,773					183,773
Expense consulting services	83,850						83,850
Net loss for the year	(595,140)							(595,140)
Ending balance at Dec. 31, 2015	8,942,496	$ 0	$ 29,031	$ 2,329,508	$ 32,185,499	$ 1,132,168	$ (13,800)	$ (26,719,890)
Ending balance, shares at Dec. 31, 2015		0	29,030,925
Net loss for the year	(351,916)
Ending balance at Mar. 31, 2016	$ 8,546,549

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ (351,916)	$ (111,201)	$ (595,140)	$ (1,025,393)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	50,268	79,668	333,950	264,340
Stock and options issued for services	106,384	79,591	253,358	272,804
Loss on disposal of assets			31,731	3,295
Stock-based compensation			327,748	899,438
Changes in:
Accounts receivable	506,685	286,840	(747,069)	(588,672)
Prepaid expenses	16,068	(10,206)	(42,530)	(16,322)
Accounts payable	(380,115)	(37,241)	11,819	11,633
Revenue share payable	(852,792)	(339,459)	852,847	215,210
Accrued expenses	1,107	5,392	(18,476)	13,459
Deferred revenue	618,224	133,308	106,872	(106,142)
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	(286,087)	86,692	515,110	(56,350)
CASH FLOWS FROM INVESTING ACTIVITIES:
Patent rights	(1,295)	(3,042)	(1,519)	(110,551)
Equipment	(14,507)		(2,046)	(6,984)
Website site development costs		(19,800)	(97,399)	(292,417)
NET CASH USED IN INVESTING ACTIVITIES	(15,802)	(22,842)	(100,964)	(409,952)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repurchase of common stock payable	(357,415)
Proceeds from issuance of common stock			4,346,446	8,795,032
Redemption of common and preferred stock				(6,000,000)
NET CASH USED IN FINANCING ACTIVITIES	(357,415)		4,346,446	2,795,032
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(659,304)	63,850	4,760,592	2,328,730
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD	8,207,565	3,446,973	3,446,973	1,118,243
CASH AND CASH EQUIVALENTS - END OF PERIOD	7,548,261	3,510,823	8,207,565	3,446,973
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	163
Cash paid for income taxes
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued for future services

Nature of Business and Basis of Presentation	3 Months Ended	12 Months Ended
Nature of Business and Basis of Presentation	Mar. 31, 2016	Dec. 31, 2015
Nature of Business and Basis of Presentation [Abstract]
NATURE OF BUSINESS AND BASIS OF PRESENTATION	NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION We are a technology solution company focused on the health care industry. Our objective is to bring better access to better care by leveraging our proprietary technology to provide on demand savings and clinical messaging within physicians’ and patients’ web based platforms, including Electronic Health Records, e-prescribing platforms, pharmacies and Patient Portals. Initially defined as a marketing and advertising company through its consumer website, OptimizeRx.com, we have matured as a technology solutions provider through our direct to physician solutions, which allows physicians to automatically display and distribute sample vouchers and/or co-pay coupons electronically within the ePrescription platform to pharmacies on behalf of their patients. The OptimizeRx solution is integrated into the ePrescribing or Electronic Medical Records applications, but can also be accessed on their mobile device as well as an application on a prescriber’s desktop. Our solutions provide health care institutions with an alternative option to the traditional inefficiencies and issues associated with storing and managing physical drug samples and pre-printed coupons and provides better access and affordability to patients to improve affordability, adherence, education and outcomes. In turn, we provide pharmaceutical manufacturers with both direct to consumer and direct to physician channels for more efficiently communicating and promoting their products and savings with a method of transparent return on investment. The consolidated financial statements for the three month periods ended March 31, 2016 and 2015 have been prepared by us without audit pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. In the opinion of management, all adjustments necessary to present fairly our financial position, results of operations, and cash flows as of March 31, 2016 and 2015, and for the periods then ended, have been made. Those adjustments consist of normal and recurring adjustments. The consolidated balance sheet as of December 31, 2015, has been derived from the audited consolidated balance sheet as of that date. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as filed with the U.S. Securities and Exchange Commission. The results of operations for the three month period ended March 31, 2016, are not necessarily indicative of the results to be expected for the full year. Certain reclassifications have been made in the prior period’s consolidated financial statements to conform to the current period’s presentation.	NOTE 1 – NATURE OF BUSINESS OptimizeRx Corporation is a technology solutions company targeting the healthcare industry. Our objective is to bring better access to better healthcare through connecting patients, physicians and pharmaceutical manufacturers through technology. Originally defined as a marketing and advertising company through our consumer website, we have matured into a technology solutions provider with our direct to physician solution, SampleMD. SampleMD allows physicians to search, print and send available sample trial vouchers and/or co-pay coupons on behalf of their patients. The SampleMD solution is integrated into the physician’s ePrescribing or Electronic Health Record applications, but can also be a stand-alone desktop application. OptimizeRx solutions provide pharmaceutical manufacturers a direct to physician channel for communicating and promoting their products. It allows healthcare providers a means to provide sampling and coupons without having to physically store samples on site, and it provides better access and affordability to patients. The company was originally formed as Optimizer Systems, LLC in the State of Michigan on January 31, 2006. It converted its form to a corporation on October 22, 2007 and changed its name to OptimizeRx Corporation. On April 14, 2008, RFID, Ltd., a Colorado corporation, consummated a reverse merger by entering into a share exchange agreement with the stockholders of OptimizeRx Corporation, pursuant to which the stockholders of OptimizeRx Corporation exchanged all of the issued and outstanding capital stock of OptimizeRx Corporation for 1,256,958 shares of common stock of RFID, Ltd., representing 100% of the outstanding capital stock of RFID, Ltd. As of April 30, 2008, RFID’s officers and directors resigned their positions and RFID changed its business to OptimizeRx’s business. On April 15, 2008, RFID, Ltd.’s corporate name was changed to OptimizeRx Corporation. On September 4, 2008, a migratory merger was completed, thereby changing the state of incorporation from Colorado to Nevada, resulting in the current corporate structure, in which OptimizeRx Corporation, a Nevada corporation, is the parent corporation, and OptimizeRx Corporation, a Michigan corporation, is its wholly-owned subsidiary (together, "OptimizeRx" and "the Company").

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2015

Summary of Significant Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

Accounting Basis

The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting). The Company has adopted a December 31 fiscal year-end.

Principles of Consolidation

The financial statements reflect the consolidated results of OptimizeRx Corporation (a Nevada corporation) and its wholly owned subsidiary, OptimizeRx Corporation (a Michigan corporation). All material inter-company transactions have been eliminated in the consolidation.

Cash and Cash Equivalents

For purposes of the accompanying financial statements, the Company considers all highly liquid instruments with an initial maturity of three months or less to be cash equivalents.

Fair Value of Financial Instruments

The fair value of cash, accounts receivable, prepaid expenses, accounts payable, accounts payable – related party, accrued expenses and deferred revenue approximates the carrying amount of these financial instruments due to their short-term nature.

Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including our own credit risk.

In addition to defining fair value, the disclosure requirements around fair value establish a fair value hierarchy for valuation inputs, which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

Level 1 – inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

Level 2 – inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The Company’s stock options and warrants are valued using level 3 inputs.

The carrying value of the Company’s financial assets and liabilities, which consist of cash, accounts receivable, prepaid expenses, patent rights, web development costs, accounts payable, accounts payable – related party, accrued expenses and deferred revenue, are valued using level 1 inputs. The Company believes that the recorded values approximate their fair value due to the short maturity of such instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, exchange or credit risks arising from these financial instruments.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates. Because the Company’s customers are primarily large well-capitalized companies, historically there has been very little bad debt expense. Bad debt expense was $0 for each of the years ended December 31, 2015 and 2014. The allowance for doubtful accounts was $0 as of both December 31, 2015 and 2014.

Property and Equipment

Capital assets are being depreciated over their estimated useful lives of three to seven years using the straight-line method of depreciation for book purposes.

Revenue Recognition and Revenue Share Expense

Revenue is recognized when it is earned. Revenues are primarily generated from our content delivery activities in which we deliver eCoupons and eVouchers through a distribution network of ePrescribers and Electronic Health Record technology providers (channel partners), or from reselling services that complement our business for other of our partners.

We recognize setup fees that are required for integrating client offerings and campaigns into our rule-based content delivery system and network upon completion of the setup when the client’s campaign is ready to launch within our system. As the eCoupons and or eVouchers are distributed through our platform and network of channel partners (a transaction), these transactions are recorded and revenue is recognized at the time of distribution. Revenue for transactions can be realized based on a price per distribution, a price per redemption, or as a flat fee over a period of time, depending on the client contract. Additionally, the Company also recognizes revenue for providing program performance reporting and maintenance, either by the Company directly delivering reports or by providing access to its online reporting portal that the client can utilize. These fees are charged monthly and recognized as recurring monthly revenue.

In some instances, we also resell products and or services that are available through our channel partners, and that are complementary to our core business and client base. In these instances, net revenue is recognized based on the commission based revenue split that the Company receives.

Based on the volume of transactions that are delivered through our channel partner network, we provide a revenue share to compensate the partner for their promotion of the campaign. Revenue shares are a negotiated percentage of the transaction fees and can also be specific to special considerations and campaigns. In addition, we pay revenue share to PDR/LDM as a result of a 2014 legal settlement in an amount equal to the greater of 10% of eCoupon distribution revenues generated or $0.37 per eCoupon distributed. The contractual amount due to our channel partners is recorded as an expense at the time the eCoupon is distributed.

Income Taxes

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the carrying value of assets, depreciable and amortizable lives of tangible and intangible assets, the carrying value of liabilities, the amount of revenue to be billed, and the timing of revenue recognition and related revenue share expenses. Actual results could differ from these estimates.

Concentration of Credit Risks

The Company maintains its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences financial difficulties.

Research and Development

The Company expenses research and development expenses as incurred. Our research efforts are focused on understanding the market dynamics that have the potential to affect the business and increase revenue in both the short and long term. Our primary goal is to increase revenue by helping patients better afford and access the medicines their doctors prescribe, as well as other healthcare products and services they need. Based on this, the Company continually seeks ways to improve its technology to enhance user experiences, and to develop new services and solutions for its customers.

Share-based Payments

The Company uses the fair value method to account for stock-based compensation. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered. The fair value of each award is estimated on the date of each grant. For restricted stock, the fair market value is based on the market value of the stock granted on the date of the grant. For options, it is estimated using the Black=Scholes option pricing model that uses the assumptions noted in the following table. Estimated volatilities are based on the historical volatility of the Company’s stock over the same period as the expected term of the options. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The Company uses historical data to estimate option exercise behavior and to determine this term. The risk free rate used is based on the U.S. Treasury yield curve in effect at the time of the grant using a time period equal to the expected option term. The Company has never paid dividends and does not expect to pay any dividends in the future.

	2015			2014

Expected dividend yield		0	%		0	%
Risk free interest rate		0.24% - 0.93%			0.90% - 1.44%
Expected option term		2.5 - 3.5 years			3.5 years
Turnover/forfeiture rate		0	%		0	%
Expected volatility		67% - 85%			117% - 138%

The Black-Scholes option valuation model and other existing models were developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. These option valuation models require the input of, and are highly sensitive to, subjective assumptions including the expected stock price volatility. OptimizerRx’s stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions could materially affect the fair value estimate.

Loss Per Common and Common Equivalent Share

The computation of basic earnings per common share is computed using the weighted average number of common shares outstanding during the year. The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year plus common stock equivalents, which would arise from the exercise of warrants outstanding using the treasury stock method and the average market price per share during the year. Options, warrants and convertible preferred stock have not been included in the diluted earnings per share calculation for either year since their effect is anti-dilutive in all years presented.

Impairment of Long-Lived Assets

The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.

Recently Issued Accounting Guidance

The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Prepaid Expenses

12 Months Ended

Dec. 31, 2015

Prepaid Expenses [Abstract]

PREPAID EXPENSES

NOTE 3 – PREPAID EXPENSES

Prepaid expenses consisted of the following as of December 31, 2015 and 2014:

	2015		2014
Insurance	$	30,623	$	18,093
Rent		-0-		-0-
Legal		40,000		10,000
Total prepaid expenses	$	70,623	$	28,093

Property and Equipment

12 Months Ended

Dec. 31, 2015

Property and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 4 – PROPERTY AND EQUIPMENT

The Company owned equipment recorded at cost which consisted of the following as of December 31, 2015 and 2014:

	2015			2014
Computer equipment	$	21,565		$	19,519
Furniture and fixtures		11,088			11,088
Subtotal		32,653			30,607
Accumulated depreciation		(22,414	)		(17,794	)
Property and equipment, net	$	10,239		$	12,813

Depreciation expense was $4,620 and $5,933 for the years ended December 31, 2015 and 2014, respectively.

Web-Based Technology

12 Months Ended

Dec. 31, 2015

Web-Based Technology [Abstract]

WEB-BASED TECHNOLOGY

NOTE 5 – WEB-BASED TECHNOLOGY

The Company has capitalized costs in developing its web-based technology, which consisted of the following as of December 31, 2015 and 2014:

	2015			2014
OptimizeRx web-based technology	$	154,133		$	154,133
SampleMD web-based technology		602,517			602,517
SampleMD 2.0 web-based technology		537,877			440,477
Subtotal, web-based technology		1,294,527			1,197,127
Accumulated amortization		(954,057	)		(692,484	)
Web-based technology, net	$	340,470		$	504,643

Amortization is recorded using the straight-line method over a period of up to five years. During 2014, the Company launched its SampleMD 2.0 web-based technology. All remaining carrying value at December 31, 2015 relates to the SampleMD 2.0 web-based technology. Amortization expense for the web-based technology costs was $261,572 and $192,760 for the years ended December 31, 2015 and 2014, respectively.

Patent and Trademarks

12 Months Ended

Dec. 31, 2015

Patent and Trademarks [Abstract]

PATENT AND TRADEMARKS

NOTE 6 – PATENT AND TRADEMARKS

On April 26, 2010, the Company acquired the technical contributions and assignment of all exclusive rights to and for a key patent from an officer and shareholder in exchange for 300,000 shares of common stock to be granted at the discretion of the seller and 200,000 stock options, which expired in April 2015, that were valued at $360,000. The shares were valued on the grant date at $570,000 and have been recorded as a payable to the related party.

The Company has capitalized costs in purchasing and defending its patent, which consisted of the following as of December 31, 2015 and 2014:

	2015			2014
Patent rights and intangible assets	$	930,000		$	930,000
Patent defense costs		172,457			170,937
New patents and trademarks		58,469			90,202
Accumulated amortization		(328,042	)		(260,285	)
Patent rights and intangible assets, net	$	832,884		$	930,854

The Company began amortizing the patent, using the straight-line method over the estimated useful life of 17 years, once it was put into service in July 2010. In 2013, the Company began incurring costs related to defense of the patent. These costs have been capitalized and will be amortized using the straight-line method over the remaining useful life of the original patent. Amortization expense was $67,758 and $65,647 for the years ended December 31, 2015 and 2014, respectively.

Deferred Revenue	12 Months Ended
Deferred Revenue	Dec. 31, 2015
Deferred Revenue [Abstract]
DEFERRED REVENUE	NOTE 7 – DEFERRED REVENUE The Company has several signed contracts with customers for the distribution of coupons, or other services, which include payment in advance. The payments are not recorded as revenue until the revenue is earned under its revenue recognition policy discussed in Note 2. Deferred revenue was $227,002 and $120,130 as of December 31, 2015 and 2014, respectively.

- Definition

The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

Stockholders Equity	3 Months Ended
Stockholders Equity	Mar. 31, 2016
Stockholders Equity/Common Stock/Preferred Stock [Abstract]
STOCKHOLDERS EQUITY	NOTE 2 – STOCKHOLDERS EQUITY As described in greater detail in Note 4, related party transactions, in February 2016, we made a one-time payment of $720,415 to our previous CEO in lieu of issuing shares owed to him from prior years. A portion of this payment, $357,415, was for 295,384 shares of common stock reflected in stock payable at December 31, 2015. In March 2016, we issued 12,500 shares of common stock to Independent Directors in connection with our Director Compensation plan which calls for issuance of 6,250 shares per quarter to each Independent Director. These shares were valued at $13,125. In January 2015, we issued 12,500 shares of common stock to our Independent Directors in connection with the same compensation plan. Those shares were recorded as stock payable at December 31, 2014. In addition, we recorded an additional 12,500 shares, valued at $16,375 as stock payable at March 31, 2015 for shares to be issued in April 2015. In February 2015, we entered into a capital markets advisory agreement covering a one year period, which calls for 90,000 shares of common stock to be issued as compensation. These shares were valued at $112,500 and are being amortized to expense over the period of service. Of these shares, 45,000 were issued in March 2015, and the balance were issued in August 2015.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Share Based Payments - Options	3 Months Ended
Share Based Payments - Options	Mar. 31, 2016
Share Based Payments - Options/ Stock Option [Abstract]
SHARE BASED PAYMENTS - OPTIONS	NOTE 3 – SHARE BASED PAYMENTS – OPTIONS We use the fair value method to account for stock based compensation. We recorded $79,459 and $53,841 in compensation expense in the periods ended March 31, 2016 and 2015, respectively, related to options issued under our stock-based incentive compensation plan. This includes expense related to options issued in prior years for which the requisite service period for those options includes the current year as well as options issued in the current year. The fair value of these instruments was calculated using the Black-Scholes option pricing model. Information related to the assumptions used in this model is set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

Related Party Transactions	3 Months Ended	12 Months Ended
Related Party Transactions	Mar. 31, 2016	Dec. 31, 2015
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 4 – RELATED PARTY TRANSACTIONS In February 2016, after hiring a new CEO, we paid our previous CEO $720,415 in lieu of issuing him 595,384 shares of common stock based on the 50 day average price of $1.21 per share. A total of 295,384 of these shares were due as a result of previously granted stock awards in 2014 and 2015, for which shares had not yet been issued. These shares were recorded as stock payable on the balance sheet at December 31, 2015. The remaining 300,000 shares were due in connection with the purchase of a patent from the previous CEO in 2010. These shares were recorded as accounts payable – related party on the balance sheet at December 31, 2015. The difference between the value the shares were initially recorded at in 2010 and the amount they were redeemed at in 2016 was recorded as additional paid in capital. Also, in April 2016, we and the previous CEO entered into a separation agreement and an 18 month consulting agreement, both of which we recently disclosed in a Form 8-K that we filed with the U.S. Securities and Exchange Commission. The consulting agreement set forth the terms of the previous CEO’s continued relationship with our company. He remained our employee through March 31, 2016 and the consulting agreement began April 1, 2016. Under the terms of the consulting agreement, he will receive a monthly payment of $15,000, with the potential for up to $54,000 in additional bonus payments during the term of the agreement. This agreement also calls for total payments of $12,425 related to insurance benefits. The separation agreement and consulting agreement replace and supersede all previously disclosed payments related to his severance and board fees.	NOTE 8 – RELATED PARTY TRANSACTIONS During the year ended December 31, 2010, the Company acquired the technical contributions and assignment of all exclusive rights to and for the SampleMD patent in process at the time from an officer and shareholder in exchange for 300,000 shares of common stock to be granted at the discretion of the seller and 200,000 stock options, which expired in April 2015, that were valued at $360,000. The shares were valued on the grant date at $570,000 and have been recorded as a payable to the related party. During the year ended December 31, 2015, WPP made a strategic investment in the Company and is a shareholder that owns approximately 20% of the shares of the Company. During 2015, we had billings of $420,503 to agencies that are part of the WPP group and recognized revenue of $178,855 related to those billings. As of December 31, 2015, we have receivables included in trade receivables on the balance sheet of $381,125 from WPP agencies and amounts due to WPP agencies included in revenue share payable of $37,803 as of December 31, 2015.

Common Stock

12 Months Ended

Dec. 31, 2015

Stockholders Equity/Common Stock/Preferred Stock [Abstract]

COMMON STOCK

NOTE 9 – COMMON STOCK

The Company has 500,000,000 shares of common stock, $.001 par value per share, authorized as of December 31, 2015. There were 29,030,925 and 22,867,319 shares of common stock issued and outstanding at December 31, 2015 and 2014, respectively.

In September, 2015, we entered into a securities purchase agreement pursuant to which we sold 6,011,106 shares of our common stock for $0.7875 per share, or gross proceeds of $4,733,746. The shares were issue to a subsidiary of WPP, the world’s largest marketing services company, as part of a strategic investment by WPP. Placement agents in the offering received commissions and expenses of $387,300, or approximately 8.2% of the gross proceeds. The net proceeds received were $4,346,446. Placement agents also received warrants to purchase up to 240,444 shares of our common stock with an exercise price of $0.7875 per share and a term of 5 years. The warrants were valued at $176,213 and have been recorded as equity issuance costs.

In 2014, the Company adopted a Director Compensation plan covering its independent non-employee Directors. A total of 50,000 shares, valued at $60,125, were granted and issued in 2015 in connection with this compensation plan. A total of 19,565 shares were granted in 2014 with a total value of $23,166. A total of 7,065 of these shares were issued in 2014 and the remaining 12,500 shares were included in stock payable at December 31, 2014 and issued in January 2015.

In February, 2015, we entered into a capital markets advisory agreement covering a one-year period, which called for 90,000 shares of common stock to be issued as compensation. These shares were valued at $112,500 and were amortized to expense over the period of service. 45,000 of these shares were issued in March 2015. The agreement was terminated in July 2015, effective in August, and the remaining 45,000 shares were not issued. The total expense recognized was $56,250.

In June, 2015, we agreed to grant 197,605 fully vested shares of our common stock to two executive officers as bonuses. These shares have not been issued, but are recorded as stock payable and can be requested by the officers at any time.

In September, 2015 we entered into a new capital markets advisory agreement covering a one-year period, which called for 90,000 shares of common stock to be issued as compensation. The first 45,000 shares were issued in September 2015 and valued at $41,400. These shares are being amortized over a six-month period. The agreement was cancelled in February 2016 and the remaining 45,000 shares will not be issued.

In March 2014, the Company entered into a securities purchase agreement, pursuant to which the Company sold 8,333,333 shares of the Company’s common stock for $1.20 per share, or gross proceeds of $10,000,000.

Placement agents in the offering received commissions equal to approximately 9.7% of gross proceeds, for an aggregate commission of approximately $970,000, including reimbursements for their reasonable out of pocket expenses. Placement agents also received warrants to purchase up to 804,139 shares of the Company's common stock with an exercise price of $1.20 per share and a term of 5 years. The warrants were valued at $1,110,211, have been recorded as equity issuance costs, and were registered on a registration statement dated May 28, 2014. In addition to the warrants to placement agents, the Company also paid cash bonuses of $240,000 to three executive officers, agreed to issue 200,000 shares to three executive officers, and issued 150,000 shares to a consultant, in connection with the equity raise. The stock was valued based on the fair market value on the grant date, which was $630,000 in total. These amounts have been recorded as equity issuance costs, resulting in total equity issuance costs of $2.95 million. The 200,000 shares for the three executive officers have not been issued, but are recorded as stock payable and can be requested by the respective officers at any time.

The Company used the net proceeds of the 2014 offering to exercise the securities redemption option agreement, as amended, with Vicis Capital Master Fund that provided the Company with an option to purchase all of the outstanding shares and derivative securities held by Vicis for total payment of $6,000,000. The shares and derivative securities included the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Common Stock, and warrants to purchase shares of common stock held by Vicis in the Company. The balance of the net proceeds was used for working capital purposes.

In January 2014, an officer exercised 500,000 stock warrants using the cashless exercise feature included in the warrants. In exchange for the 500,000 warrants, 410,348 shares of common stock were issued. In October 2014, a consultant exercised 50,000 stock warrants using the cashless exercise feature included in the warrants. In exchange for the 50,000 warrants, 35,417 shares of common stock were issued.

In February 2014, the Company agreed to grant 337,500 shares of common stock, half of which vested immediately and half of which vested in August 2014, to two executive officers as bonuses based on their efforts to recapitalize the Company to secure approximately $3 million in working capital while reducing potential fully diluted shares by approximately 7 million shares. Stock-based compensation related to these bonuses was $570,375 during the year ended December 31, 2014. These shares have not yet been issued and are recorded as stock payable, but can be requested by the officers at any time.

On June 1, 2013, the Company entered into a consulting agreement with North Coast Advisors, Inc. for various services. The Company agreed to issue 20,000 shares of common stock as of the date of the contract. The Company also agreed to issue an additional 20,000 shares every six months in alignment with the agreement renewal up to the two years of the agreement. The first 20,000 shares were valued at the Company’s common stock closing price as of the date of the contract, which was $1.945/share; and the second 20,000 shares were valued at the Company’s common stock closing price of $1.50/share on the date of issuance, and have been expensed. An additional 10,000 shares were issued in 2014 before the agreement was terminated by the Company. The 2014 shares were valued at $1.85, the closing price of the Company’s common stock on the date of issuance.

On June 10, 2013, the Company entered into a capital markets advisory agreement with Taglich Brothers, Inc. for various services. The agreement covered a one-year period and the Company agreed to issue 44,000 shares of common stock to Taglich over the term of the agreement. The shares were valued at $1.66, the closing price of the stock on the date of the agreement and were written off over the term of the agreement. The shares were issued in June 2014 upon expiration of the contract.

On September 20, 2013, the Company entered into a separation agreement that included post-employment consulting services with a former CEO of the Company. The Company agreed to issue 500,000 shares of common stock, 250,000 shares immediately and 250,000 by January 1, 2014. The shares were issued and the Company recognized the entire issuance in the December 31, 2013 shares outstanding. The shares were valued at $505,000 and $174,808 of that amount remained as deferred stock compensation as of December 31, 2013, but was fully amortized to expense in 2014.

Preferred Stock	12 Months Ended
Preferred Stock	Dec. 31, 2015
Stockholders Equity/Common Stock/Preferred Stock [Abstract]
PREFERRED STOCK	NOTE 10 – PREFERRED STOCK Series A Preferred During the year ended December 31, 2008, 35 preferred shares were issued for $3,500,000. Issuance costs totaled $515,000 resulting in net proceeds of $2,985,000. The 35 shares were convertible into 3,500,000 shares of common stock and bore a 10% cumulative dividend. In addition, there was a warrant issued to purchase 6,000,000 shares of common stock at an exercise price of $2 for a period of seven years. The holders of the preferred stock were entitled to semi-annual dividends payable on the stated value of the Series A preferred stock at a rate of 10% per annum, which was cumulative, and accrued daily from the issuance date. The dividends may be paid in cash or shares of the Company's common stock at management’s discretion. If after the conversion eligibility date, the market price for the common stock for any ten consecutive trading days in which the stock trades for over $2 per share and trading exceeds 100,000 shares per day, the preferred shareholders can be required to convert their shares to common stock. Each share of Series A preferred stock was convertible at the option of the holder into that number of shares of common stock of the Company at the stated value of such share at a $1 conversion price. The holder could cause this conversion at the time the shares were eligible for resale by the holder. The conversion price was subject to adjustment as hereinafter provided, at any time, or from time to time upon the terms and in the manner hereinafter set forth in the shareholder agreement. There was no conversion expiration date, however, the holder must provide 30 days notice for the registration of the conversion. On May 12, 2010, the Company’s Board declared and issued 236,598 common shares as payment for all cumulative and current semi-annual dividends. On November 16, 2010, the Company’s Board declared and issued 173,922 common shares for its semi-annual dividend payment. On March 25, 2011, the Company’s Board declared and issued 176,768 common shares for its semi-annual dividend payment. On September 21, 2011, the Company's Board declared and issued 156,306 common shares for its semi-annual dividend payment. The Company had undeclared dividends that were due in February and September 2012 totaling $350,000 and undeclared dividends of $350,000 that were due in February and September 2013 for a total undeclared amount of $700,000 as of December 31, 2013. As described in greater detail in Note 9, all of the Series A Preferred shares were redeemed in 2014. Series B Preferred During the year ended December 31, 2010, 15 preferred shares were issued for $1,500,000. The 15 shares were convertible into 1,000,000 shares of common stock and bore a 10% cumulative dividend. In addition, there was a warrant issued to purchase 3,000,000 shares of common stock at an exercise price of $3 for a period of seven years. The preferred stock was issued for $1,500,000 less associated issuance costs of $350,000 for net proceeds of $1,150,000. Additionally, 3,000,000 common stock warrants were issued with the preferred stock. Based on the fair values of the preferred stock and common stock warrants on the issue date, $341,100 was allocated to preferred stock and $1,158,900 was allocated to the common stock warrants. Equity issuance costs of $350,000 were allocated to the preferred stock. During the quarter ended September 30, 2011, 15 preferred shares were issued to an investor for $1,500,000. The 15 shares were convertible into 1,000,000 shares of common stock and bore a 10% cumulative dividend. In addition, there was a warrant issued to purchase 1,000,000 shares of common stock at an exercise price of $3 for a period of seven years. Based on the fair values of the preferred stock and common stock warrants on the issue date, $855,460 was allocated to preferred stock and $644,540 was allocated to the common stock warrants. See Note 12. The holders of the preferred stock were entitled to semi-annual dividends payable on the stated value of the Series B preferred stock at a rate of 10% per annum, which was cumulative, and accrued daily from the issuance date. The dividends may be paid in cash or shares of the Company's common stock at management’s discretion. If after the conversion eligibility date, the market price for the common stock for any ten consecutive trading days in which the stock trades for over $2 per share and trading exceeds 100,000 shares per day, the preferred shareholders can be required to convert their shares to common stock. Each share of Series B preferred stock was convertible at the option of the holder into that number of shares of common stock of the Company at the stated value of such share at a $1.50 conversion price. The holder could cause this conversion at the time the shares were eligible for resale by the holder. The conversion price was subject to adjustment as hereinafter provided, at any time, or from time to time upon the terms and in the manner hereinafter set forth in the shareholder agreement. On March 25, 2011, the Company’s Board declared and issued 75,758 common shares for its semi-annual dividend payment. On September 21, 2011, the Company's Board declared and issued 66,988 common shares for its semi-annual dividend payment. The Company had undeclared dividends that were due in February and September 2012 totaling $150,000 and undeclared dividends of $150,000 that were due in February and September 2013 for a total undeclared amount of $300,000 as of December 31, 2013. As described in greater detail in Note 9, all of the Series B Preferred shares were redeemed in 2014.

Stock Options

12 Months Ended

Dec. 31, 2015

Share Based Payments - Options/ Stock Option [Abstract]

STOCK OPTIONS

NOTE 11 – STOCK OPTIONS

The Company sponsors a stock-based incentive compensation plan known as the 2013 Equity Compensation Plan (the “Plan”), which was established by the Board of Directors of the Company in June 2013. A total of 1,500,000 shares were initially reserved for issuance under the Plan, of which 1,085,000 options have been granted and remain outstanding and 735,105 shares have been granted, but not issued. Of the shares granted but not issued, the Company has committed to retire 295,384 of those shares for cash. The Company has no remaining shares available to grant under the Plan, but intends to amend the Plan to increase the number of shares authorized.

The Plan allows the Company to grant incentive stock options, non-qualified stock options, stock appreciation right, or restricted stock. The incentive stock options are exercisable for up to ten years, at an option price per share not less than the fair market value on the date the option is granted. The incentive stock options are limited to persons who are regular full-time employees of the Company at the date of the grant of the option. Non-qualified options may be granted to any person, including, but not limited to, employees, independent agents, consultants and attorneys, who the Company’s Board or Compensation Committee believes have contributed, or will contribute, to the success of the Company. Non-qualified options may be issued at option prices of less than fair market value on the date of grant and are exercisable for up to ten years from date of grant. The option vesting schedule for options granted is determined by the Compensation Committee of the Board of Directors at the time of the grant. The Plan provides for accelerated vesting of unvested options if there is a change in control, as defined in the Plan.

Prior to establishment of the Plan, the Board granted options under terms similar to those described in the preceding paragraphs.

The compensation cost that has been charged against income related to options for the years ended December 31, 2015 and 2014, was $253,358 and $272,804, respectively. No income tax benefit was recognized in the income statement and no compensation was capitalized in any of the years presented.

The Company had the following option activity during the years ended December 31, 2015 and 2014:

	Number of Options			Weighted average exercise price
Outstanding, January 1, 2014		1,180,000		$	.97
Granted - 2014		387,500			1.73
Exercised - 2014		0			0
Expired – 2014		(260,000	)		(0.39	)
Balance, December 31, 2014		1,307,500			1.31
Granted – 2015		550,000			1.25
Exercised – 2015		0			0
Expired – 2015		(242,500	)		(1.68	)
Balance, December 31, 2015		1,615,000		$	1.09

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Warrants

12 Months Ended

Dec. 31, 2015

Warrants [Abstract]

WARRANTS

NOTE 12 –WARRANTS

The Company has issued warrants, primarily in connection with capital raising activities. As discussed in Note 9, in 2015, we issued 240,444 warrants, with an exercise price of $0.7875 per share in connection with the strategic investment by WPP. As also discussed in Note 9, in 2014 we issued 804,139 warrants, with an exercise price of $1.20 per share, in connection with a $10 million equity raise, the proceeds of which were used to retire common stock, preferred, stock, and previously existing warrants.

The Company had the following warrants outstanding as of December 31, 2015:

Number of Warrants	Exercise Price		Expiration Date

1,000,000	$	2.25		10/5/2017
50,000	$	0.89		2/17/2016
804,139	$	1.20		3/17/2019
240,444	$	0.7875		9/24/2020

The Company had the following warrant activity during the years ended December 31, 2015 and 2014:

	Number of Warrants			Weighted average exercise price
Outstanding, January 1, 2014		11,750,000		$	2.27
Granted		804,139			1.20
Exercised		(550,000			(0.35
Cancelled		(10,000,000			(2.40
Expired		(150,000	)		(1.45	)
Balance, December 31, 2014		1,854,139			1.69
Granted		240,444			0.7875
Balance, December 31, 2015		2,094,583		$	1.65

Operating Leases

12 Months Ended

Dec. 31, 2015

Operating Leases [Abstract]

OPERATING LEASES

NOTE 13 – OPERATING LEASES

The Company signed the lease for its current office space located in Rochester Michigan on December 1, 2011 at an approximate rent of $5,000 per month. The initial lease term was for three years with an option to renew for an additional two years at approximately $5,200 per month. The lease was renewed and now expires on November 30, 2016.

Minimum annual rent payments are as follows for the remainder term of the lease:

Year ended December 31, 2016			57,217
Total lease commitment		$	57,217

Major Customers

12 Months Ended

Dec. 31, 2015

Major Customer [Abstract]

MAJOR CUSTOMERS

NOTE 14 – MAJOR CUSTOMERS

The Company had the following major customers that individually accounted for 10% or more of revenue in any one of the years presented

	2015		Percentage			2014		Percentage
Eli Lilly and Company	$	1,409,720		20	%	$	1,270,064		20	%
Alcon Laboratories, Inc.		958,653		13	%		797,972		12	%
Astellas Pharma US, Inc.		341,555		5	%		772,320		12	%
Daiichi Sanyko, Inc.		541,201		7	%		644,702		10	%
Pfizer		521,317		7	%		628,741		10	%
All other customers		3,448,232		48	%		2,389,163		36	%

Total	$	7,220,678		100	%	$	6,502,962		100	%

Income Taxes

12 Months Ended

Dec. 31, 2015

Income Taxes [Abstract]

INCOME TAXES

NOTE 15 – INCOME TAXES

As of December 31, 2015, the Company had net operating loss carry forwards of approximately $9.1 million that expire from 2027 through 2035 that are available to offset future taxable income. The Company was formed in 2006 as a limited liability company and changed to a corporation in 2007. Activity prior to incorporation is not reflected in the Company’s corporate tax returns. In the future, the cumulative net operating loss carry-forward for income tax purposes may differ from the cumulative financial statement loss due to timing differences between book and tax reporting.

The provision for Federal income tax consists of the following for the years ended December 31, 2015 and 2014:

	2015			2014
Federal income tax benefit attributable to:
Current operations	$	202,000		$	349,000
Permanent and Timing Differences (net)		(218,000	)		(160,000	)
Valuation allowance		16,000			(189,000	)
Net provision for federal income tax	$	0		$	0

The cumulative tax effect at the expected rate of 34% of significant items comprising our net deferred tax amount is as follows as of December 31, 2015 and 2014:

	2015			2014
Deferred tax asset attributable to:
Net operating loss carryover	$	3,110,000		$	3,126,000
Valuation allowance		(3,110,000	)		(3,126,000	)
Net deferred tax asset	$	0		$	0

Under certain circumstances issuance of common shares can result in an ownership change under Internal Revenue Code Section 382 which limits the Company’s ability to utilize carry forwards from prior to the ownership change. Any such ownership change resulting from stock issuances and redemptions could limit the Company’s ability to utilize any net operating loss carry forwards or credits generated before this change in ownership. These limitations can limit both the timing of usage of these laws, as well as the loss of the ability to use these net operating losses. It is likely that the fundraising activities of 2014 and 2015 have resulted in such an ownership change.

Commitments and Contingent Liabilities	3 Months Ended	12 Months Ended
Commitments and Contingent Liabilities	Mar. 31, 2016	Dec. 31, 2015
Commitments and Contingent Liabilities [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 5 – CONTINGENCIES Litigation The company is currently involved in the following legal proceedings. In September, 2014, we initiated litigation against Shadron Stastney, our CEO from January to December 2013, in the U.S. District Court in the Eastern District of Michigan as a result of a dispute related to his separation agreement. Mr. Stastney alleged damages related to the non-registration of shares that he was granted as part of his separation agreement signed in September 2013. Under the terms of the contract we are not obligated to register the shares and we deny any obligation to do so. We have requested declarative relief from the court and also requested an injunction from the court preventing Mr. Stastney from continuing to pursue his claims. Mr. Stastney has filed a counterclaim requesting damages of $450,000 related to the non-registration of his shares. The parties are currently in the discovery process and a dispositive motion has been filed by Mr. Stastney. We are in the process of preparing our response to the motion. In March, 2015, we initiated litigation against LDM Group, LLC and PDR Network, LLC in the U.S. District Court in the Eastern District of Missouri related to the breach by LDM, and PDR as successor, of the settlement agreement signed February 28, 2014 related to previous litigation with LDM. LDM has failed to live up to its obligations under the settlement agreement including, but not limited to, not allowing us to distribute our eCoupon programs in the LDM network, not allowing us to distribute the LDM patient education programs, and not providing other information required under the settlement agreement. We are seeking enforcement of the settlement agreement and we are seeking damages in an amount at least equal to the amounts paid to date to LDM under the settlement agreement, which is in excess of $1.0 million, as well as damages for lost income and business value as a result of LDM’s breach of the agreement. In March, 2015, we also initiated litigation against PDR Network, LLC in the U.S. District Court in the District of New Jersey as a result of PDR’s breach of the Master Services Agreement between the parties requiring PDR to exclusively use our eCoupon solution. We assert that PDR’s acquisition of LDM and the use of the LDM network to distribute coupons by PDR violates the agreement between the parties and we are seeking damages in an amount at least equal the amounts paid to date by us to LDM under the settlement agreement, which is in excess of $1.0 million, as well as damages for lost income and business value as a result of PDR’s actions. In May, 2015, we filed an amended complaint in the Missouri case to consolidate the two cases and withdrew the case against PDR Networks in the U.S. District Court in the District of New Jersey, without prejudice. In July, 2015, the U.S. District Court for the Eastern District of Missouri dismissed the case, citing lack of Federal jurisdiction in the matter. We refiled the consolidated case against PDR Network and LDM group in State court in Missouri. The defendants have filed a motion to dismiss two of the four counts in the consolidated complaint. In January, 2016, the Court dismissed one of our four claims, but allowed the other three to continue forward. The parties are currently in the discovery process.	NOTE 16 – COMMITMENTS AND CONTINGENT LIABILITIES Legal The Company is currently involved in the following legal proceedings. In September, 2014, we initiated litigation against Shadron Stastney, our previous CEO, in the U.S. District Court in the Eastern District of Michigan as a result of a dispute related to his separation agreement. Mr. Stastney alleged damages related to the non-registration of shares that he was granted as part of his separation agreement signed in September 2013. Under the terms of the contract we are not obligated to register the shares and we deny any obligation to do so. We have requested declarative relief from the court and also requested an injunction to prevent Mr. Stastney from continuing to pursue his claims. Mr. Stastney has filed a counterclaim requesting damages in the amount of at least $450,000 related to the nonregistration of his shares. The parties are currently in the discovery process and a dispositive motion has been filed by Mr. Stastney. We are in the process of preparing our response to the motion. In March, 2015, we initiated litigation against LDM Group, LLC and PDR Network, LLC in the U.S. District Court in the Eastern District of Missouri related to the breach by LDM, and PDR as successor, of the settlement agreement signed February 28, 2014 to resolve previous litigation with LDM. LDM breached its obligations under the settlement agreement including, but not limited to, not allowing us to distribute our eCoupon programs in the LDM network, not allowing us to distribute the LDM patient education programs, and not providing other information required under the settlement agreement. We are seeking enforcement of the settlement agreement and damages in an amount at least equal to the amounts paid to date to LDM under the settlement agreement, which is in excess of $1.0 million, as well as damages for lost income and business value as a result of LDM’s breach of the agreement. In March, 2015, we also initiated litigation against PDR Network, LLC in the U.S. District Court in the District of New Jersey as a result of PDR’s breach of the Master Services Agreement between the parties requiring PDR to exclusively use our eCoupon solution. We assert that PDR’s acquisition of LDM and the use of the LDM network to distribute coupons by PDR violates the agreement between the parties. We are seeking damages in an amount at least equal the amounts paid to date by us to LDM under the settlement agreement, which is in excess of $1.0 million, as well as damages for lost income and business value as a result of PDR’s actions. In May, 2015, we filed an amended complaint in the Missouri case to consolidate the two cases and withdrew the case against PDR Networks in the U.S. District Court in the District of New Jersey, without prejudice. In July, 2015, the U.S. District Court for the Eastern District of Missouri dismissed the case, citing lack of Federal jurisdiction in the matter. We refiled the consolidated case against PDR Network and LDM group in State court in Missouri. The defendants filed a motion to dismissal of our claims except those for breach of contract. In January, the Court dismissed two of six claims asserted against LDM and PDR but allowed the remainder of our claims to continue forward. The parties are currently engaged in in the discovery process. Revenue-share contracts The Company has contacts with various Electronic Health Records systems and ePrescribe platforms, whereby we agree to share a portion of the revenue we generate for eCoupons distributed through their networks. These contracts grant audit rights related to the payments to our partners, and in some cases would require us to pay for the audit if the audit determined there was an underpayment and the underpayment meets certain thresholds, such as 10%. Separation benefits In February 2016, the Company hired a new CEO. The previous CEO will terminate as an employee effective March 31, 2016, but remain non-executive chairman of the Board. In connection with his separation from service, he will receive severance pay of 24 months, totaling approximately $405,000 and the Company will redeem 595,384 unissued common shares owing to him for an additional payment of $720,415. This includes the 300,000 shares described in Note 8, related party transactions, and 295,384 shares currently reflected in stock payable on the balance sheet. Allscripts Agreement In 2015, we signed an amendment to our Allscripts agreement whereby we became its exclusive eCoupon supplier and Allscripts agreed to integrate our eCoupon functionality into its Touchworks platform. Under the terms of this agreement, we agreed to pay $900,000 in two installments. The first installment of $250,000 was due and paid in November 2015. The second installment of $650,000 is due when the e-Coupon functionality is launched on a widespread basis in the Touchworks platform, which is currently expected to be in early 2017. If e-Coupon functionality is not launched by February, 2018, the initial payment of $250,000 will be refunded.

Retirement Plan	12 Months Ended
Retirement Plan	Dec. 31, 2015
Retirement Plan [Abstract]
RETIREMENT PLAN	NOTE 17 – RETIREMENT PLAN The Company sponsors a defined contribution 401(k) profit sharing plan which was adopted in December, 2015, effective in January 2016. Under the terms of the plan, the Company matches 100% of the first 3% of payroll contributed by the employee and 50% of the next 2% of payroll contributed by the employee to a maximum of 4% of an employee’s payroll. There was no expense under this plan in either 2014 or 2015, as the plan became effective in 2016.

Subsequent Events	3 Months Ended	12 Months Ended
Subsequent Events	Mar. 31, 2016	Dec. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 6 – SUBSEQUENT EVENTS In accordance with ASC 855-10, we have analyzed our operations subsequent to March 31, 2016 through the date these financial statements were issued and have determined that we do not have any material subsequent events to disclose in these financial statements other than the events described below. In April 2016, we issued 34,235 shares of common stock in connection with the cashless exercise of an expiring option to purchase 100,000 shares of common stock previously granted to a consultant.	NOTE 18 – SUBSEQUENT EVENTS In accordance with ASC 855-10, the Company has analyzed its operations subsequent to December 31, 2015 through the date these financial statements were issued and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described below. In February 2016, we made the payment of $720,415 described in more detail in Note 16 to redeem shares of stock due to our former CEO.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2015

Summary of Significant Accounting Policies [Abstract]

Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

Accounting Basis

Principles of Consolidation

Cash and Cash Equivalents

For purposes of the accompanying financial statements, the Company considers all highly liquid instruments with an initial maturity of three months or less to be cash equivalents.

Fair Value of Financial Instruments

Level 1 – inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

Accounts Receivable and Allowance for Doubtful Accounts

Property and Equipment

Capital assets are being depreciated over their estimated useful lives of three to seven years using the straight-line method of depreciation for book purposes.

Revenue Recognition and Revenue Share Expense

Income Taxes

Use of Estimates

Concentration of Credit Risks

Research and Development

Share-based Payments

	2015			2014

Expected dividend yield		0	%		0	%
Risk free interest rate		0.24% - 0.93%			0.90% - 1.44%
Expected option term		2.5 - 3.5 years			3.5 years
Turnover/forfeiture rate		0	%		0	%
Expected volatility		67% - 85%			117% - 138%

Loss Per Common and Common Equivalent Share

Impairment of Long-Lived Assets

Recently Issued Accounting Guidance

The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2015

Summary of Significant Accounting Policies [Abstract]

Summary of share based compensation fair value assumption methodology

	2015			2014

Expected dividend yield		0	%		0	%
Risk free interest rate		0.24% - 0.93%			0.90% - 1.44%
Expected option term		2.5 - 3.5 years			3.5 years
Turnover/forfeiture rate		0	%		0	%
Expected volatility		67% - 85%			117% - 138%

Prepaid Expenses (Tables)

12 Months Ended

Dec. 31, 2015

Prepaid Expenses [Abstract]

Schedule of prepaid expenses

	2015		2014
Insurance	$	30,623	$	18,093
Rent		-0-		-0-
Legal		40,000		10,000
Total prepaid expenses	$	70,623	$	28,093

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2015

Property and Equipment [Abstract]

Schedule of property and equipment

	2015			2014
Computer equipment	$	21,565		$	19,519
Furniture and fixtures		11,088			11,088
Subtotal		32,653			30,607
Accumulated depreciation		(22,414	)		(17,794	)
Property and equipment, net	$	10,239		$	12,813

Web-Based Technology (Tables)

12 Months Ended

Dec. 31, 2015

Web-Based Technology [Abstract]

Schedule of capitalized costs in developing web-based technology

	2015			2014
OptimizeRx web-based technology	$	154,133		$	154,133
SampleMD web-based technology		602,517			602,517
SampleMD 2.0 web-based technology		537,877			440,477
Subtotal, web-based technology		1,294,527			1,197,127
Accumulated amortization		(954,057	)		(692,484	)
Web-based technology, net	$	340,470		$	504,643

Patent and Trademarks (Tables)

12 Months Ended

Dec. 31, 2015

Patent and Trademarks [Abstract]

Schedule of Patent and Trademarks

	2015			2014
Patent rights and intangible assets	$	930,000		$	930,000
Patent defense costs		172,457			170,937
New patents and trademarks		58,469			90,202
Accumulated amortization		(328,042	)		(260,285	)
Patent rights and intangible assets, net	$	832,884		$	930,854

Stock Options (Tables)

12 Months Ended

Dec. 31, 2015

Share Based Payments - Options/ Stock Option [Abstract]

Schedule of share based option activity

	Number of Options			Weighted average exercise price
Outstanding, January 1, 2014		1,180,000		$	.97
Granted - 2014		387,500			1.73
Exercised - 2014		0			0
Expired – 2014		(260,000	)		(0.39	)
Balance, December 31, 2014		1,307,500			1.31
Granted – 2015		550,000			1.25
Exercised – 2015		0			0
Expired – 2015		(242,500	)		(1.68	)
Balance, December 31, 2015		1,615,000		$	1.09

Warrants (Tables)

12 Months Ended

Dec. 31, 2015

Warrants [Abstract]

Schedule of warrants outstanding

Number of Warrants	Exercise Price		Expiration Date

1,000,000	$	2.25		10/5/2017
50,000	$	0.89		2/17/2016
804,139	$	1.20		3/17/2019
240,444	$	0.7875		9/24/2020

Schedule of warrant activity

	Number of Warrants			Weighted average exercise price
Outstanding, January 1, 2014		11,750,000		$	2.27
Granted		804,139			1.20
Exercised		(550,000			(0.35
Cancelled		(10,000,000			(2.40
Expired		(150,000	)		(1.45	)
Balance, December 31, 2014		1,854,139			1.69
Granted		240,444			0.7875
Balance, December 31, 2015		2,094,583		$	1.65

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Operating Leases (Tables)

12 Months Ended

Dec. 31, 2015

Operating Leases [Abstract]

Schedule of minimum annual rent payments

Year ended December 31, 2016			57,217
Total lease commitment		$	57,217

Major Customers (Tables)

12 Months Ended

Dec. 31, 2015

Major Customer [Abstract]

Schedule of major customers individual revenue

	2015		Percentage			2014		Percentage
Eli Lilly and Company	$	1,409,720		20	%	$	1,270,064		20	%
Alcon Laboratories, Inc.		958,653		13	%		797,972		12	%
Astellas Pharma US, Inc.		341,555		5	%		772,320		12	%
Daiichi Sanyko, Inc.		541,201		7	%		644,702		10	%
Pfizer		521,317		7	%		628,741		10	%
All other customers		3,448,232		48	%		2,389,163		36	%

Total	$	7,220,678		100	%	$	6,502,962		100	%

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2015

Income Taxes [Abstract]

Federal income tax benifit

	2015			2014
Federal income tax benefit attributable to:
Current operations	$	202,000		$	349,000
Permanent and Timing Differences (net)		(218,000	)		(160,000	)
Valuation allowance		16,000			(189,000	)
Net provision for federal income tax	$	0		$	0

Deferred tax assets

	2015			2014
Deferred tax asset attributable to:
Net operating loss carryover	$	3,110,000		$	3,126,000
Valuation allowance		(3,110,000	)		(3,126,000	)
Net deferred tax asset	$	0		$	0

Nature of Business and Basis of Presentation (Details) - shares	Apr. 14, 2008	Dec. 31, 2015
Nature of Business (Textual)
Shares issued by RFID, Ltd. pursuant to a share exchange agreement	1,256,958
Percentage of stock of owned by RFID	100.00%	20.00%

Summary of Significant Accounting Policies (Details)	12 Months Ended
Summary of Significant Accounting Policies (Details)	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology
Expected dividend yield	0.00%	0.00%
Risk free interest rate minimum	0.24%	0.90%
Risk free interest rate maximum	0.93%	1.44%
Expected option term		3 years 6 months
Turnover/forfeiture rate	0.00%	0.00%
Expected volatility minimum	67.00%	117.00%
Expected volatility maximum	85.00%	138.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology
Expected option term	2 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology
Expected option term	3 years 6 months

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Summary of Significant Accounting Policies (Textual)
Bad debt expense	$ 0	$ 0
Allowance for doubtful accounts	$ 0	$ 0
Revenue recognition and revenue shares, Description	Legal settlement in an amount equal to the greater of 10% of eCoupon distribution revenues generated or $0.37 per eCoupon distributed.
Maximum [Member]
Summary of Significant Accounting Policies (Textual)
Property and equipment, estimated useful lives	7 years
Minimum [Member]
Summary of Significant Accounting Policies (Textual)
Property and equipment, estimated useful lives	3 years

Prepaid Expenses (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Prepaid Expenses [Abstract]
Insurance		$ 30,623	$ 18,093
Rent		0	0
Legal		40,000	10,000
Total prepaid expenses	$ 54,555	$ 70,623	$ 28,093

Property and Equipment (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, Subtotal		$ 32,653	$ 30,607
Accumulated depreciation		(22,414)	(17,794)
Property and equipment, net	$ 23,076	10,239	12,813
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Subtotal		21,565	19,519
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Subtotal		$ 11,088	$ 11,088

Property and Equipment (Details Textual) - USD ($)	12 Months Ended
Property and Equipment (Details Textual) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Property and Equipment (Textual)
Depreciation expense	$ 4,620	$ 5,933

Web-Based Technology (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Web-based technology, Subtotal		$ 1,294,527	$ 1,197,127
Accumulated amortization		(954,057)	(692,484)
Web-based technology, net	$ 308,812	340,470	504,643
OptimizeRx web-based technology [Member]
Finite-Lived Intangible Assets [Line Items]
Web-based technology, Subtotal		154,133	154,133
SampleMD web-based technology [Member]
Finite-Lived Intangible Assets [Line Items]
Web-based technology, Subtotal		602,517	602,517
SampleMD 2.0 web-based technology [Member]
Finite-Lived Intangible Assets [Line Items]
Web-based technology, Subtotal		$ 537,877	$ 440,477

Web-Based Technology (Details Textuals) - USD ($)	12 Months Ended
Web-Based Technology (Details Textuals) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Web Based Technology (Textual)
Web-based technology amortization period, Description	Over a period of up to five years.
Web-based technology, amortization expense	$ 261,572	$ 192,760

Patent and Trademarks (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Patent and Trademarks [Abstract]
Patent rights and intangible assets		$ 930,000	$ 930,000
Patent defense costs		172,457	170,937
New patents and trademarks		58,469	90,202
Accumulated amortization		(328,042)	(260,285)
Patent rights and intangible assets, net	$ 817,239	$ 832,884	$ 930,854

Patent and Trademarks (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
Patent and Trademarks (Details Textual) - USD ($)	Apr. 26, 2010	Dec. 31, 2015	Mar. 31, 2016	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Accounts payable - related party		$ 570,000		$ 570,000
Amortizing patent		Straight-line method.
Useful life		17 years
Amortization expense		$ 67,758		$ 65,647
SampleMD Patent Member]
Finite-Lived Intangible Assets [Line Items]
Issuance of common stock: for cash shares	300,000
Stock options	200,000
Shares values	$ 360,000
Expire date	Apr. 30, 2015

Deferred Revenue (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Deferred Revenue [Abstract]
Deferred revenue	$ 845,226	$ 227,002	$ 120,130

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References + Details

Stockholders Equity (Details) - USD ($)	1 Months Ended		3 Months Ended		12 Months Ended
Stockholders Equity (Details) - USD ($)	Feb. 29, 2016	Feb. 28, 2015	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Jan. 31, 2015	Oct. 31, 2014
Related Party Transaction [Line Items]
Common stock payable, Amount			$ 357,415
Common stock, shares issued			29,043,425		29,030,925	22,867,319		35,417
Common stock value			$ 29,043		$ 29,031	$ 22,867
Share based compensation expense					$ 327,748	$ 899,438
CEO [Member]
Related Party Transaction [Line Items]
Common stock payable, Amount	$ 357,415
Common stock, shares issued	295,384
Related party transaction	$ 720,415
Director [Member]
Related Party Transaction [Line Items]
Common stock, shares issued			12,500				12,500
Common stock value			$ 13,125
Called for issuance of shares			6,250
Additional shares issued				12,500
Additional shares issued, Value				$ 16,375
Capital markets advisory agreement [Member]
Related Party Transaction [Line Items]
Share based compensation expense		$ 112,500
Called for issuance of shares		90,000
Shares issued				45,000

Share Based Payments - Options (Details) - USD ($)	3 Months Ended		12 Months Ended
Share Based Payments - Options (Details) - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Share Based Payments - Options (Textual)
Stock-based compensation expense			$ 327,748	$ 899,438

Related Party Transactions (Details) - USD ($)		1 Months Ended		12 Months Ended
Related Party Transactions (Details) - USD ($)	Apr. 01, 2016	Feb. 29, 2016	Apr. 26, 2010	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2016	Apr. 14, 2008
Related Party Transaction [Line Items]
Accounts Payable, Related Parties, Current				$ 570,000	$ 570,000
Payable to related party				420,503
Recognized revenue				178,855
Trade receivables				$ 381,125
Percentage of ownership by WPP				20.00%			100.00%
Revenue payable				$ 37,803
Total common granted stock				550,000	387,500
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Shares of common stock issued		595,384
Lieu of common stock issued		$ 720,415
Average price per shares		$ 1.21
Subsequent Event [Member]
Related Party Transaction [Line Items]
Total common granted stock	12,425
Subsequent Event [Member] \| Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Monthly payment of consulting agreement	$ 15,000
Additional bonus payments	$ 54,000
Patents [Member]
Related Party Transaction [Line Items]
Shares of common stock issued			300,000
Stock options			200,000
Expire date			Apr. 30, 2015
Shares values			$ 360,000

Common Stock (Details) - USD ($)	1 Months Ended								3 Months Ended		12 Months Ended
Common Stock (Details) - USD ($)	Sep. 30, 2015	Jul. 31, 2015	Jun. 30, 2015	Feb. 28, 2015	Oct. 31, 2014	Mar. 31, 2014	Feb. 28, 2014	Jan. 31, 2014	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Jan. 02, 2014	Dec. 31, 2013	Sep. 20, 2013	Jun. 10, 2013	Jun. 01, 2013
Class of Stock [Line Items]
Common stock, shares authorized									500,000,000		500,000,000	500,000,000
Common stock par value									$ 0.001		$ 0.001	$ 0.001
Common stock, shares issued					35,417				29,043,425		29,030,925	22,867,319
Common stock, shares outstanding									29,043,425		29,030,925	22,867,319
Common stock value, Issued									$ 29,043		$ 29,031	$ 22,867
Deferred stock compensation											13,800
Net proceeds received									$ (357,415)		4,346,446	2,795,032
Gross proceeds											$ 60,125	$ 41,667
Common stock issued for equity issuance costs						$ 630,000
Employee bonus, Value							$ 337,500
Employee bonus, Share												570,375
Additional working capital							$ 3,000,000
Fully diluted shares							7,000,000
Equity issuance cost						$ 2,950,000
Shares granted											550,000	387,500
Warrants exercised, number of shares					50,000							500,000
Redeem shares for cash												$ (6,000,000)
Consulting Agreement [Member]
Class of Stock [Line Items]
Common stock par value																	$ 1.945
Common stock, shares issued																	20,000
Additional shares issued												10,000					20,000
Common stock price per share												$ 1.85					$ 1.50
Capital Markets Advisory Agreement [Member]
Class of Stock [Line Items]
Common stock par value																$ 1.66
Common stock, shares issued																44,000
Additional shares issued										45,000
Redeem shares for cash, shares				90,000
Redeem shares for cash		$ 56,250		$ 112,500
Number of shares not be issued		45,000
Separation Agreement [Member]
Class of Stock [Line Items]
Common stock, shares issued													250,000		250,000
Common stock value, Issued														$ 505,000
Deferred stock compensation														$ 174,808
Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Sales of common stock	6,011,106					8,333,333
Warrant exercise price period	5 years					5 years
Sale of stock price per share	$ 0.7875					$ 1.20
Gross proceeds	$ 4,733,746					$ 10,000,000
Purchase of warrants	240,444
Warrants, Value	$ 176,213
New Capital Markets Advisory Agreement [Member]
Class of Stock [Line Items]
Redeem shares for cash, shares	90,000
New Capital Markets Advisory Agreement Shares Issued First [Member]
Class of Stock [Line Items]
Sale of common stock value	$ 41,000
Sale of common stock shares	45,000
Placement agents [Member]
Class of Stock [Line Items]
Commissions and expenses description	Placement agents in the offering received commissions and expenses of $387,300, or approximately 8.2% of the gross proceeds.
Commissions percentage						9.70%
Commissions						$ 970,000
Purchase of warrants						804,139
Warrants, Value						$ 1,110,211
Three executive officers [Member]
Class of Stock [Line Items]
Additional shares issued						200,000
Employee Bonus						$ 240,000
Consultant [Member]
Class of Stock [Line Items]
Additional shares issued						150,000
Vicis Capital Master Fund [Member]
Class of Stock [Line Items]
Debt redemption, amount												$ 6,000,000
Officer [Member]
Class of Stock [Line Items]
Additional shares issued								410,348
Warrants exercised, number of shares								500,000
Director [Member]
Class of Stock [Line Items]
Common stock, shares issued												12,500
Additional shares issued												7,065
Shares granted											50,000	19,565
Granted value											$ 60,125	$ 23,166
Two officers [Member]
Class of Stock [Line Items]
Employee bonus, Share			197,605

Preferred Stock (Details) - USD ($)		1 Months Ended					12 Months Ended
Preferred Stock (Details) - USD ($)	May 12, 2010	Sep. 30, 2011	Sep. 21, 2011	Mar. 25, 2011	Nov. 16, 2010	Dec. 31, 2008	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2010	Dec. 31, 2013	Sep. 30, 2013	Sep. 30, 2012
Class of Stock [Line Items]
Stock issued, Values							$ 4,346,446	$ 8,795,032
Common Stock
Class of Stock [Line Items]
Stock issued, Shares							6,011,106	8,333,333
Stock issued, Values							$ 6,011	$ 8,333
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Stock issued, Shares	236,598		156,306	176,768	173,922	35
Stock issued, Values						$ 3,500,000
Issuance costs						515,000
Net proceeds of shares						$ 2,985,000
Preferred Shares issued, shares						3,500,000
Percentage of cumulative dividend						10.00%	10.00%
Warrants issued						6,000,000
Exercise price						$ 2	$ 2
Term of warrant						7 years
Treasury stock							100,000
Conversion price							$ 1
Total Undeclared dividends										$ 700,000	$ 350,000	$ 350,000
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Stock issued, Shares		15							15
Stock issued, Values		$ 1,500,000					$ 1,500,000		$ 1,500,000
Issuance costs							350,000
Net proceeds of shares							$ 1,150,000
Preferred Shares issued, shares		1,000,000							1,000,000
Percentage of cumulative dividend		10.00%					10.00%		10.00%
Warrants issued		1,000,000							3,000,000
Exercise price		$ 3					$ 2		$ 3
Term of warrant		7 years							7 years
Treasury stock							100,000
Conversion price							$ 1.50
Total Undeclared dividends										$ 300,000	$ 150,000	$ 150,000
Series B Preferred Stock [Member] \| Common Stock
Class of Stock [Line Items]
Stock issued, Shares			66,988	75,758
Stock issued, Values		$ 644,540
Issuance costs							$ 350,000
Preferred shares issued, values							$ 1,158,900
Warrants issued							3,000,000
Warrants, Value		$ 855,460					$ 341,100

Stock Options (Details) - $ / shares	12 Months Ended
Stock Options (Details) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Number of Options
Beginning balance ,shares	1,307,500	1,180,000
Granted	550,000	387,500
Exercised	0	0
Expired	(242,500)	(260,000)
Ending balance, shares	1,615,000	1,307,500
Weighted average exercise price
Beginning balance	$ 1.31	$ 0.97
Granted	1.25	1.73
Exercised	0	0
Expired	(1.68)	(0.39)
Ending balance	$ 1.09	$ 1.31

Stock Options (Detail Textuals) - USD ($)	12 Months Ended
Stock Options (Detail Textuals) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	550,000	387,500
Available for grant, shares	1,615,000	1,307,500	1,180,000
2013 Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares initially reserved for issuance	1,500,000
Options granted	1,085,000
Shares granted	735,105
Available for grant, shares	295,384	410,000
Compensation cost	$ 253,358	$ 272,804

Warrants (Details)	12 Months Ended
Warrants (Details)	Dec. 31, 2015 $ / shares shares
Warrant [Member]
Number of Warrants \| shares	1,000,000
Exercise Price \| $ / shares	$ 2.25
Expiration Date	Oct. 05, 2017
Warrant one [Member]
Number of Warrants \| shares	50,000
Exercise Price \| $ / shares	$ 0.89
Expiration Date	Feb. 17, 2016
Warrant two [Member]
Number of Warrants \| shares	804,139
Exercise Price \| $ / shares	$ 1.20
Expiration Date	Mar. 17, 2019
Warrant three [Member]
Number of Warrants \| shares	240,444
Exercise Price \| $ / shares	$ 0.7875
Expiration Date	Sep. 24, 2020

Warrants (Details 1) - Warrant [Member] - $ / shares	12 Months Ended
Warrants (Details 1) - Warrant [Member] - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Number of Warrants
Beginning balance	1,854,139	11,750,000
Granted	240,444	804,139
Exercised		(550,000)
Cancelled		(10,000,000)
Expired		(150,000)
Ending balance	2,094,583	1,854,139
Weighted average exercise price
Beginning balance	$ 1.69	$ 2.27
Granted	0.7875	1.20
Exercise		(0.35)
Cancelled		(1.45)
Expired		(2.40)
Ending balance	$ 1.65	$ 1.69

Warrants (Details Textuals) - Warrant [Member] - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Issueds of warrants	240,444	804,139
Granted, weighted average	$ 0.7875	$ 1.20
Proceed from warrant issued		$ 10

Operating Leases (Details)	Dec. 31, 2015 USD ($)
Operating Leases [Abstract]
Year ended December 31, 2016	$ 57,217
Total lease commitment	$ 57,217

Major Customers (Details) - USD ($)	3 Months Ended		12 Months Ended
Major Customers (Details) - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Revenue, Major Customer [Line Items]
Total	$ 1,759,528	$ 1,487,553	$ 7,220,678	$ 6,502,962
Revenues Percentage			100.00%	100.00%
Eli Lilly and Company [Member]
Revenue, Major Customer [Line Items]
Total			$ 1,409,720	$ 1,270,064
Revenues Percentage			20.00%	20.00%
Alcon Laboratories, Inc. [Member]
Revenue, Major Customer [Line Items]
Total			$ 958,653	$ 797,972
Revenues Percentage			13.00%	12.00%
Astellas Pharma US, Inc. [Member]
Revenue, Major Customer [Line Items]
Total			$ 341,555	$ 772,320
Revenues Percentage			5.00%	12.00%
Daiichi Sanyko, Inc. [Member]
Revenue, Major Customer [Line Items]
Total			$ 541,201	$ 644,702
Revenues Percentage			7.00%	10.00%
Pfizer [Member]
Revenue, Major Customer [Line Items]
Total			$ 521,317	$ 628,741
Revenues Percentage			7.00%	10.00%
All other customers [Member]
Revenue, Major Customer [Line Items]
Total			$ 3,448,232	$ 2,389,163
Revenues Percentage			48.00%	36.00%

Major Customers (Detail Textuals)	12 Months Ended
Major Customers (Detail Textuals)	Dec. 31, 2015
Major Customer [Abstract]
Total revenue percentage	10.00%

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Federal income tax benefit attributable to:
Current operations	$ 202,000	$ 349,000
Permanent and Timing Differences (net)	(218,000)	(160,000)
Valuation allowance	16,000	(189,000)
Net provision for federal income tax	$ 0	$ 0

Income Taxes (Details 1) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred tax asset attributable to:
Net operating loss carryover	$ 3,110,000	$ 3,126,000
Valuation allowance	(3,110,000)	(3,126,000)
Net deferred tax asset	$ 0	$ 0

Income Taxes (Detail Textuals) $ in Millions	12 Months Ended
Income Taxes (Detail Textuals) $ in Millions	Dec. 31, 2015 USD ($)
Income Taxes [Abstract]
Operating loss carryforwards	$ 9.1
Operating loss expire description	Expire from 2027 through 2035 that are available to offset future taxable income.
Effective rate of tax expected	34.00%

Commitments and Contingent Liabilities (Details) - USD ($)	1 Months Ended	12 Months Ended
	Feb. 29, 2016	Dec. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014
Commitments and Contingent Liabilities (Textual)
Claims pertaining to damages to nonregistration of shares						$ 450,000
Contingent Liabilities related to audit fees in percentage		10.00%
Stock payable		$ 1,132,148	$ 663,670		$ 963,063
Allscripts agreement payment		900,000
Installment 1 [Member]
Commitments and Contingent Liabilities (Textual)
Allscripts agreement payment		250,000
Installment 2 [Member]
Commitments and Contingent Liabilities (Textual)
Allscripts agreement payment		$ 650,000
Former CEO [Member]
Commitments and Contingent Liabilities (Textual)
Severance costs	$ 405,000
Redemption of unissued common shares	595,384
Redemption of unissued common shares payment	$ 720,415
Related party transactions shares	300,000
Stock payable	$ 295,384
LDM Group [Member]
Commitments and Contingent Liabilities (Textual)
Damage related to LDM' s breach of the agreement				$ 1,000,000
PDR Network [Member]
Commitments and Contingent Liabilities (Textual)
Damage related to LDM' s breach of the agreement				$ 1,000,000

Retirement Plan (Details)	12 Months Ended
Retirement Plan (Details)	Dec. 31, 2015
Retirement Plan [Abstract]
Percentage of payroll contributed, discription	Terms of the plan, the Company matches 100% of the first 3% of payroll contributed by the employee and 50% of the next 2% of payroll contributed by the employee to a maximum of 4% of an employee's payroll. There was no expense under this plan in either 2014 or 2015, as the plan became effective in 2016.

Subsequent Events (Details) - USD ($)	1 Months Ended	12 Months Ended
Subsequent Events (Details) - USD ($)	Apr. 30, 2016	Dec. 31, 2015	Dec. 31, 2014	Feb. 29, 2016
Subsequent Events (Textual)
Shares of common stock in connection with cashless exercise of option		0	0
Expiring option to purchase shares of common stock		242,500	260,000
Former CEO [Member]
Subsequent Events (Textual)
Redemption of unissued common shares payment				$ 720,415
Subsequent Event [Member] \| Consultant [Member]
Subsequent Events (Textual)
Shares of common stock in connection with cashless exercise of option	34,235
Expiring option to purchase shares of common stock	100,000